The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Induction of Robust B Cell Responses after Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells
Open accessAbstract
Modified mRNA vaccines have developed into an effective and well-tolerated vaccine platform that offers scalable and precise antigen production. Nevertheless, the immunological events leading to strong antibody responses elicited by mRNA vaccines are largely unknown. In this study, we demonstrate that protective levels of antibodies to hemagglutinin were induced after two immunizations of modified non-replicating mRNA encoding influenza H10 encapsulated in lipid nanoparticles (LNP) in non-human primates. While both intradermal (ID) and intramuscular (IM) administration induced protective titers, ID delivery generated this response more rapidly. Circulating H10-specific memory B cells expanded after each immunization, along with a transient appearance of plasmablasts. The memory B cell pool waned over time but remained detectable throughout the 25-week study. Following prime immunization, H10-specific plasma cells were found in the bone marrow and persisted over time. Germinal centers were formed in vaccine-draining lymph nodes along with an increase in circulating H10-specific ICOS+ PD-1+ CXCR3+ T follicular helper cells, a population shown to correlate with high avidity antibody responses after seasonal influenza vaccination in humans. Collectively, this study demonstrates that mRNA/LNP vaccines potently induce an immunological repertoire associated with the generation of high magnitude and quality antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“several studies have shown that i.m. delivery of 1mΨ-modified mRNA vaccines results in the rapid and potent induction of follicular T helper cells (Tfh) [71,72].”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [71]
In the citing paper
“Additionally, the robust and sustained antigen expression of nucleoside-modified mRNA was associated with more optimal antibody responses compared to unmodified mRNA [12,13].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Follicular Helper CD4 T Cells (T FH )
Crotty, S. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101400 · Cited by 2,738
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Interferon-γ and B Cell Stimulatory Factor-1 Reciprocally Regulate Ig Isotype Production
Snapper, C. M., & Paul, W. E. (1987) · Science · doi:10.1126/science.3107127 · Cited by 1,927
Victora, G. D., & Nussenzweig, M. C. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075032 · Cited by 1,878
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
Correlates of protection induced by vaccination
Plotkin, S. A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00131-10 · Cited by 1,745
The generation of antibody-secreting plasma cells
Nutt, S. L., Hodgkin, P. D., Tarlinton, D. M., & Corcoran, L. M. (2015) · Nature reviews. Immunology · doi:10.1038/nri3795 · Cited by 1,565
Morita, R., Schmitt, N., Bentebibel, S.-E., Ranganathan, R., Bourdery, L., Zurawski, G., Foucat, E., Dullaers, M., Oh, S., Sabzghabaei, N., et al. (2011) · Immunity · doi:10.1016/j.immuni.2010.12.012 · Cited by 1,563
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Cited by
Sorted by citations
Alameh, M.-G., Tombácz, I., Bettini, E., Lederer, K., Ndeupen, S., Sittplangkoon, C., Wilmore, J. R., Gaudette, B. T., Soliman, O. Y., Pine, M., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.11.001 · Cited by 775
Advances in mRNA Vaccines for Infectious Diseases
Zhang, C., Maruggi, G., Shan, H., & Li, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00594 · Cited by 696
Lipid nanoparticles for nucleic acid delivery: Current perspectives
Samaridou, E., Heyes, J. A., & Lutwyche, P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.002 · Cited by 609
New Vaccine Technologies to Combat Outbreak Situations
Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01963 · Cited by 579
Pardi, N., Hogan, M. J., Naradikian, M. S., Parkhouse, K., Cain, D. W., Jones, L., Moody, M. A., Verkerke, H. P., Myles, A., Willis, E., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171450 · Cited by 530
mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases
Maruggi, G., Zhang, C., Li, J., Ulmer, J. B., & Yu, D. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.020 · Cited by 507
Kim, J., Eygeris, Y., Gupta, M., & Sahay, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.014 · Cited by 514
Innate immune mechanisms of mRNA vaccines
Verbeke, R., Hogan, M. J., Loré, K., & Pardi, N. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.014 · Cited by 535
Recent advances in mRNA vaccine technology
Pardi, N., Hogan, M. J., & Weissman, D. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.01.008 · Cited by 512
The dawn of mRNA vaccines: the COVID-19 case
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.043 · Cited by 504
Röltgen, K., Nielsen, S. C. A., Silva, O., Younes, S. F., Zaslavsky, M., Costales, C., Yang, F., Wirz, O. F., Solis, D., Hoh, R. A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.018 · Cited by 475
Feldman, R. A., Fuhr, R., Smolenov, I., (Mick) Ribeiro, A., Panther, L., Watson, M., Senn, J. J., Smith, M., Almarsson, Ӧ., Pujar, H. S., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.074 · Cited by 454
mRNA vaccine: a potential therapeutic strategy
Wang, Y., Zhang, Z., Luo, J., Han, X., Wei, Y., & Wei, X. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01311-z · Cited by 422
Lederer, K., Castaño, D., Gómez Atria, D., Oguin, T. H., Wang, S., Manzoni, T. B., Muramatsu, H., Hogan, M. J., Amanat, F., Cherubin, P., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.11.009 · Cited by 383
“Published work has shown that mRNA vaccines can induce GC B cells (Lindgren et al., 2017; Pardi et al., 2018a), but the kinetics of GC responses upon immunization with mRNA vaccines was not previously investigated.”
Laczko, D. I., Hogan, M. J., Toulmin, S. A., Hicks, P. D., Lederer, K., Gaudette, B. T., Castaño, D., Amanat, F., Muramatsu, H., Oguin, T. H., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.019 · Cited by 355
Novel approaches for vaccine development
Gebre, M. S., Brito, L. A., Tostanoski, L. H., Edwards, D. K., Carfi, A., & Barouch, D. H. (2021) · Cell · doi:10.1016/j.cell.2021.02.030 · Cited by 347
Self-citationThree decades of messenger RNA vaccine development
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100766 · Cited by 342
Freyn, A. W., Ramos da Silva, J., Rosado, V. C., Bliss, C. M., Pine, M., Mui, B. L., Tam, Y. K., Madden, T. D., de Souza Ferreira, L. C., Weissman, D., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.04.018 · Cited by 299
mRNA-based therapeutics: looking beyond COVID-19 vaccines
Parhiz, H., Atochina‐Vasserman, E. N., & Weissman, D. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02444-3 · Cited by 303
SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond
Bettini, E., & Locci, M. (2021) · Vaccines · doi:10.3390/vaccines9020147 · Cited by 292
From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases
Pilkington, E. H., Suys, E. J. A., Trevaskis, N. L., Wheatley, A. K., Zukancic, D., Algarni, A., Al-Wassiti, H. A., Davis, T. P., Pouton, C. W., Kent, S. J., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.06.023 · Cited by 271
mRNA Vaccines in the COVID-19 Pandemic and Beyond
Hogan, M. J., & Pardi, N. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042420-112725 · Cited by 260
Ghattas, M., Dwivedi, G., Lavertu, M., & Alameh, M. (2021) · Vaccines · doi:10.3390/vaccines9121490 · Cited by 275
Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines
Aldosari, B. N., Alfagih, I. M., & Almurshedi, A. S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020206 · Cited by 248
Kose, N., Fox, J. M., Sapparapu, G., Bombardi, R., Tennekoon, R. N., de Silva, A. D., Elbashir, S. M., Theisen, M. A., Humphris-Narayanan, E., Ciaramella, G., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aaw6647 · Cited by 202
Self-citationEspeseth, A. S., Cejas, P. J., Citron, M. P., Wang, D., DiStefano, D. J., Callahan, C., Donnell, G. O., Galli, J. D., Swoyer, R., Touch, S., et al. (2020) · npj Vaccines · doi:10.1038/s41541-020-0163-z · Cited by 190
Self-citationPrediction of lipid nanoparticles for mRNA vaccines by the machine learning algorithm
Wang, W., Feng, S., Ye, Z., Gao, H., Lin, J., & Ouyang, D. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.021 · Cited by 173
Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans
Cagigi, A., & Loré, K. (2021) · Vaccines · doi:10.3390/vaccines9010061 · Cited by 153
Self-citationRoute of Vaccine Administration Alters Antigen Trafficking but Not Innate or Adaptive Immunity
Ols, S., Yang, L., Thompson, E. A., Pushparaj, P., Tran, K., Liang, F., Lin, A., Eriksson, B. M., Hedestam, G. B. K., Wyatt, R. T., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.02.111 · Cited by 151
Immunological basis for enhanced immunity of nanoparticle vaccines
Kelly, H. G., Kent, S. J., & Wheatley, A. K. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1578216 · Cited by 146
mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent
Sajid, A., Matias, J., Arora, G., Kurokawa, C., DePonte, K., Tang, X., Lynn, G. E., Wu, M.-J., Pal, U., Strank, N. O., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj9827 · Cited by 140
Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines
Lee, J., Woodruff, M. C., Kim, E. H., & Nam, J. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00999-x · Cited by 141
Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines
Rijkers, G. T., Weterings, N., Obregón‐Henao, A., Dutt, T., Dutt, T. S., van Overveld, F. J., & Henao-Tamayo, M. I. (2021) · Vaccines · doi:10.3390/vaccines9080848 · Cited by 139
Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza
Chivukula, S., Plitnik, T., Tibbitts, T., Karve, S., Dias, A., Zhang, D., Goldman, R., Gopani, H., Khanmohammed, A., Sarode, A., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00420-6 · Cited by 117
Samanovic, M. I., Cornelius, A. R., Gray-Gaillard, S. L., Allen, J. R., Karmacharya, T., Wilson, J. P., Hyman, S., Tuen, M., Koralov, S. B., Mulligan, M. J., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abi8961 · Cited by 116
Wu, L., Li, X., Qian, X., Wang, S., Liu, J., & Yan, J. (2024) · Vaccines · doi:10.3390/vaccines12020186 · Cited by 137
Zhu, Y., Ma, J., Shen, R., Lin, J., Li, S., Lu, X., Stelzel, J. L., Kong, J., Cheng, L., Vuong, I., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01131-0 · Cited by 111
Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques
Pardi, N., LaBranche, C. C., Ferrari, G., Cain, D. W., Tombácz, I., Parks, R. J., Muramatsu, H., Mui, B. L., Tam, Y. K., Karikó, K., et al. (2019) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.03.003 · Cited by 103
Advances in gene-based vaccine platforms to address the COVID-19 pandemic
Pushparajah, D., Jimenez, S., Wong, S. L., Alattas, H., Nafissi, N., & Slavcev, R. A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.003 · Cited by 99
RNA-based pharmacotherapy for tumors: From bench to clinic and back
Liang, X., Li, D., Leng, S., & Zhu, X. M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109997 · Cited by 100
Messenger RNA-Based Vaccines Against Infectious Diseases
Alameh, M.-G., Weissman, D., & Pardi, N. (2020) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2020_202 · Cited by 96
Zhang, C., Ma, Y., Zhang, J., Kuo, J. C., Zhang, Z., Xie, H., Zhu, J., & Liu, T. (2022) · Molecules · doi:10.3390/molecules27061943 · Cited by 95
Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections
Versteeg, L., Almutairi, M. M., Hotez, P. J., & Pollet, J. B. K. (2019) · Vaccines · doi:10.3390/vaccines7040122 · Cited by 94
New Kids on the Block: RNA-Based Influenza Virus Vaccines
Scorza, F. B., & Pardi, N. (2018) · Vaccines · doi:10.3390/vaccines6020020 · Cited by 91
mRNA nanodelivery systems: targeting strategies and administration routes
Yuan, M., Han, Z., Liang, Y., Sun, Y., He, B., Chen, W., & Fan, L. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00425-3 · Cited by 98
Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications
Lopes, C., Cristóvão, J. S., Silvério, V., Lino, P. R., & Fonte, P. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2135502 · Cited by 88
Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics
Semple, S. C., Leone, R. D., Barbosa, C., Tam, Y. K., & Lin, P. J. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020398 · Cited by 80
Thompson, E. A., Ols, S., Miura, K., Rausch, K. M., Narum, D. L., Spångberg, M., Juraska, M., Wille-Reece, U., Weiner, A. J., Howard, R. F., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120692 · Cited by 73
mRNA vaccines: Past, present, future
Karam, M., & Daoud, G. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.05.003 · Cited by 76
Mettelman, R. C., Souquette, A. H., de Velde, L.-A. V., Vegesana, K., Allen, E. K., Kackos, C. M., Trifkovic, S., DeBeauchamp, J., Wilson, T. L., James, D. G. S., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01590-2 · Cited by 62
Current progress in the development of prophylactic and therapeutic vaccines
Li, T., Qian, C., Gu, Y., Zhang, J., Li, S., & Xia, N. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2230-4 · Cited by 59
Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans
Lin, A., Apostolović, D., Jahnmatz, M., Liang, F., Ols, S., Tecleab, T., Wu, C., van Hage, M., Solovay, K., Rubin, K., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci135020 · Cited by 58
New Technologies for Influenza Vaccines
Rockman, S. P., Laurie, K., Parkes, S., Wheatley, A. K., & Barr, I. (2020) · Microorganisms · doi:10.3390/microorganisms8111745 · Cited by 58
Willis, E., Pardi, N., Parkhouse, K., Mui, B. L., Tam, Y. K., Weissman, D., & Hensley, S. E. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aav5701 · Cited by 54
Design Strategies for and Stability of mRNA–Lipid Nanoparticle COVID-19 Vaccines
Liu, T., Tian, Y., Zheng, A., & Cui, C. (2022) · Polymers · doi:10.3390/polym14194195 · Cited by 54
Nel, A. E., & Miller, J. F. (2021) · ACS Nano · doi:10.1021/acsnano.1c01845 · Cited by 50
An Update on mRNA-Based Viral Vaccines
Jeeva, S., Kim, K., Shin, C. H., Wang, B., & Kang, S. (2021) · Vaccines · doi:10.3390/vaccines9090965 · Cited by 49
Hellgren, F., Cagigi, A., Cerveira, R. A., Ols, S., Kern, T., Lin, A., Eriksson, B., Dodds, M., Jasny, E., Schwendt, K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39421-5 · Cited by 49
Röltgen, K., Nielsen, S. C. A., Arunachalam, P. S., Yang, F., Hoh, R. A., Wirz, O. F., Lee, A. S., Gao, F., Mallajosyula, V., Li, C., et al. (2021) · doi:10.1101/2021.04.05.21254952 · Cited by 45
The Development of mRNA Vaccines for Infectious Diseases: Recent Updates
Nitika, Wei, J., & Hui, A. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s341694 · Cited by 42
Lenart, K., Hellgren, F., Ols, S., Yan, X., Cagigi, A., Cerveira, R. A., Winge, I. P., Hanczak, J., Mueller, S. O., Jasny, E., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.10.001 · Cited by 40
Influenza Viruses: Innate Immunity and mRNA Vaccines
Lee, S., & Ryu, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.710647 · Cited by 36
A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax
Kunkeaw, N., Nguitragool, W., Takashima, E., Kangwanrangsan, N., Muramatsu, H., Tachibana, M., Ishino, T., Lin, P. J. C., Tam, Y. K., Pichyangkul, S., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00786-9 · Cited by 34
Targeting the hallmarks of aging to improve influenza vaccine responses in older adults
Cadar, A. N., Martin, D. E., & Bartley, J. M. (2023) · Immunity & Ageing · doi:10.1186/s12979-023-00348-6 · Cited by 34
mRNA-Based Vaccines and Mode of Action
Gergen, J., & Petsch, B. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_230 · Cited by 36
COVID‐19: Clinical status of vaccine development to date
Kumar, S., Basu, M., Ghosh, P., Ansari, A., & Ghosh, M. K. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15552 · Cited by 32
Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals
Lederer, K., Parvathaneni, K., Painter, M. M., Bettini, E., Agarwal, D., Lundgreen, K. A., Weirick, M., Goel, R. R., Xu, X., Drapeau, E. M., et al. (2021) · doi:10.1101/2021.09.16.21263686 · Cited by 179
An old problem with new solutions: Strategies to improve vaccine efficacy in the elderly
Bell, M. R., & Kutzler, M. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114175 · Cited by 29
Nucleic acid delivery and nanoparticle design for COVID vaccines
Andresen, J. L., & Fenton, O. S. (2021) · MRS Bulletin · doi:10.1557/s43577-021-00169-2 · Cited by 32
Have mRNA vaccines sentenced DNA vaccines to death?
Cagigi, A., & Douradinha, B. G. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2282065 · Cited by 30
Ige, M. A., Ren, X., Yang, Y., Zhang, H., Shen, C., Jiang, Y., Li, J., & Wan, X. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102721 · Cited by 30
Yu, M., Charles, A., Cagigi, A., Christ, W., Österberg, B., Falck‐Jones, S., Azizmohammadi, L., Åhlberg, E., Falck‐Jones, R., Svensson, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37835-9 · Cited by 29
The race toward a universal influenza vaccine: Front runners and the future directions
Hu, L., Lao, G., Liu, R., Feng, J., Long, F., & Peng, T. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105505 · Cited by 26
Nanoparticle-based delivery platforms for mRNA vaccine development
Okay, S., Özcan, Ö. Ö., & Karahan, M. (2020) · AIMS Biophysics · doi:10.3934/biophy.2020023 · Cited by 23
Advancing mRNA Therapeutics: The Role and Future of Nanoparticle Delivery Systems
Li, J., Zhang, Y., Yang, Y., & Sun, T. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00276 · Cited by 24
Better, Faster, Stronger: mRNA Vaccines Show Promise for Influenza Vaccination in Older Adults
Bartley, J. M., Cadar, A. N., & Martin, D. E. (2021) · Immunological Investigations · doi:10.1080/08820139.2021.1909617 · Cited by 21
Lipid‐based nucleic acid therapeutics with in vivo efficacy
Sufian, M. A., & Ilies, M. A. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1856 · Cited by 23
Ackun‐Farmmer, M. A., & Jewell, C. M. (2023) · Advanced NanoBiomed Research · doi:10.1002/anbr.202200135 · Cited by 21
Chaudhari, R. H., Tandel, N., Sahu, K., Negi, S., Bashir, H., Rupareliya, A., Mishra, R. P. N., Dalai, S. K., & Tyagi, R. K. (2021) · Nanomaterials · doi:10.3390/nano11020406 · Cited by 21
Scaglione, A., Opp, S., Hurtado, A. M., Lin, Z., Pampeno, C., Noval, M. G., Thannickal, S. A., Stapleford, K. A., & Meruelo, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.719077 · Cited by 20
Wolf, M. A., O’Hara, J. M., Bitzer, G. J., Narayanan, E., Boehm, D. T., Bevere, J. R., DeJong, M. A., Hall, J. M., Wong, T. Y., Falcone, S., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00890-4 · Cited by 18
Sandberg, J. T., Ols, S., Löfling, M., Varnaitė, R., Lindgren, G., Nilsson, O., Rombo, L., Kalén, M., Loré, K., Blom, K. G., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001381 · Cited by 20
Role of T Follicular Helper Cells in Viral Infections and Vaccine Design
Ahmadivand, S., Fux, R., & Palić, D. (2025) · Cells · doi:10.3390/cells14070508 · Cited by 23
Roozen, G. V. T., Prins, M. L. M., van Binnendijk, R. S., den Hartog, G., Kuiper, V. P., Prins, C., Janse, J. J., Kruithof, A. C., Feltkamp, M. C. W., Kuijer, M., et al. (2021) · medRxiv · doi:10.1101/2021.07.27.21261116 · Cited by 18
CircRNA: Unlocking new frontiers in therapeutic and vaccine development
Bahrulolum, H., Rouzbahani, F. N., Hoseini, Z. S., Chaharmahali, M., & Hosseini, S. M. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.10.038 · Cited by 19
Boretti, A. A. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01264-1 · Cited by 25
Flynn, J. A., Weber, T., Cejas, P. J., Cox, K. S., Touch, S., Austin, L. A., Ou, Y., Citron, M. P., Luo, B., Gindy, M. E., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.063 · Cited by 16
Tjiam, M. C., Fernández, S., & French, M. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.738123 · Cited by 15
The inflammaging microenvironment induces dysfunctional rewiring of Tfh cell differentiation
Nelson, C. S., Podestà, M. A., Gempler, M., Lee, J.-M., Batty, C. J., Mathenge, P. G., Sainju, A., Chang, M., Ke, H., Chandrakar, P., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.187271 · Cited by 14
Immunology of RNA-based vaccines: The critical interplay between inflammation and expression
Tregoning, J. S., Wang, Z., Sridhar, S., Shattock, R. J., & DeRosa, F. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.011 · Cited by 21
Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review
Belay, W. Y., Nibret, G., & Aschale, Y. (2023) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s418314 · Cited by 16
Roznik, K., Xue, J., Stavrakis, G., Johnston, T. S., Kalluri, D., Ohsie, R., Qin, C. X., McAteer, J., Segev, D. L., Mogul, D. B., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00866-4 · Cited by 14
mRNA vaccines against HIV : Hopes and challenges
Zubair, A., Ahmad, H., Arif, M. M., & Ali, M. (2025) · HIV Medicine · doi:10.1111/hiv.70024 · Cited by 14
Agallou, M., Koutsoni, O. S., Michail, M., Zisimopoulou, P., Tsitsilonis, O., & Karagouni, E. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac421 · Cited by 12
Determination of significant immunological timescales from mRNA-LNP-based vaccines in humans
Moyles, I. R., Korosec, C. S., & Heffernan, J. M. (2023) · Journal of Mathematical Biology · doi:10.1007/s00285-023-01919-3 · Cited by 11
Lee, H., Punt, J. A., Miller, D. C., Nagpal, A., Smith, C., Sayeed, Y. A., Patel, J., Stojanovic, M. P., Popescu, A., & McCormick, Z. L. (2021) · Pain Medicine · doi:10.1093/pm/pnab063 · Cited by 12
Thompson, E. A., Ngecu, W., Stoddart, L., Johnston, T. S., Chang, A. Y., Cascino, K., Alejo, J. L., Abedon, A. T., Samaha, H., Rouphael, N., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.168470 · Cited by 10
Potent and Targeted Sindbis Virus Platform for Immunotherapy of Ovarian Cancer
Opp, S., Hurtado, A. M., Pampeno, C. L., Lin, Z., & Meruelo, D. (2022) · Cells · doi:10.3390/cells12010077 · Cited by 11
La nueva generación de vacunas de ARN mensajero (ARNm) frente a la gripe
Reina, J. (2021) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2021.07.009 · Cited by 11
Metadata
- Authors
- Lindgren, G., Ols, S., Liang, F., Thompson, E. A., Lin, A., Hellgren, F., Bahl, K., John, S., Yuzhakov, O., Hassett, K. J., Brito, L. A., Salter, H., Ciaramella, G., & Loré, K.
- Affiliations
- Karolinska Institutet (SE)
- Moderna Therapeutics (United States) (US)
- Corresponding author
- Loré, Karin
- ORCID
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2017-11-13
- Volume
- 8
- Pages
- 1539-1539
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC5693886
- OpenAlex
- W2767992446
- Cited by
- 132
- References
- 44
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 9 · 2023: 16 · 2022: 25 · 2021: 37 · 2020: 15 · 2019: 10 · 2018: 4
- FWCI
- 6.21
- Type
- journal article
- Language
- en
- Update notices
- corrigendum (2019-04-02)
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Karolinska Institutet
- Vetenskapsrådet
- China Scholarship Council
- Topics
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- T follicular helper cells, ICOS, PD-1, CXCR3, memory B cells, plasma cells, germinal center, intradermal vaccination, intramuscular vaccination, non-human primates, vaccine immunogenicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review